您当前所在的位置:首页 > 产品中心 > 产品信息
Biperiden_分子结构_CAS_514-65-8)
点击图片或这里关闭

Biperiden

产品号 DB00810 公司名称 DrugBank
CAS号 514-65-8 公司网站 http://www.ualberta.ca/
分子式 C21H29NO 电 话 (780) 492-3111
分子量 311.46106 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 689

产品价格信息

请登录

产品别名

标题
Biperiden
IUPAC标准名
1-{bicyclo[2.2.1]hept-5-en-2-yl}-1-phenyl-3-(piperidin-1-yl)propan-1-ol
IUPAC传统名
biperidene
商标名
Akineton
Akinophyl
别名
Biperidenum [INN-Latin]
Biperideno [INN-Spanish]
Biperiden Hydrochloride
Biperidene Hydrochloride
Biperiden [Usan:Ban:Inn:Jan]
Biperidene [INN-French]
Biperidine
Biperidine Hydrochloride
Beperiden

产品登记号

CAS号 514-65-8
PubChem SID 46508325
PubChem CID 2381

产品性质

疏水性(logP) 4.1
溶解度 25.1 mg/L

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. [PubChem]
Indication For use as an adjunct in the therapy of all forms of parkinsonism and control of extrapyramidal disorders secondary to neuroleptic drug therapy.
Pharmacology Biperiden is a weak peripheral anticholinergic agent. It has, therefore, some antisecretory, antispasmodic and mydriatic effects. In addition, biperiden possesses nicotinolytic activity. The parenteral form of biperiden is an effective and reliable agent for the treatment of acute episodes of extrapyramidal disturbances sometimes seen during treatment with neuroleptic agents. Akathisia, akinesia, dyskinetic tremors, rigor, oculogyric crisis, spasmodic torticollis, and profuse sweating are markedly reduced or eliminated. With parenteral biperiden, these drug-induced disturbances are rapidly brought under control.
Toxicity LD50=760 mg/kg (Orally in rats). Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.
Affected Organisms
Humans and other mammals
Biotransformation The metabolism of biperiden is not completely understood, but does involve hydroxylation.
Absorption 87% bioavailability
Protein Binding 60%
References
Nishiyama K, Mizuno T, Sakuta M, Kurisaki H: Chronic dementia in Parkinson's disease treated by anticholinergic agents. Neuropsychological and neuroradiological examination. Adv Neurol. 1993;60:479-83. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

参考文献

  • Nishiyama K, Mizuno T, Sakuta M, Kurisaki H: Chronic dementia in Parkinson's disease treated by anticholinergic agents. Neuropsychological and neuroradiological examination. Adv Neurol. 1993;60:479-83. Pubmed